Background. Persistent or recurrent hyperthyroidism after treatment with radioactive iodine (RAI) is common and many patiedlxnts require either additional doses or surgery before they are cured. The purpose of this study was to identify patterns and predictors of failure of RAI in patients with hyperthyroidism. Methods. We conducted a retrospective review of patients treated with RAI from 2007 to 2010. Failure of RAI was defined as receipt of additional dose(s) and/or total thyroidectomy. Using a Cox proportional hazards model, we conducted univariate analysis to identify factors associated with failure of RAI. A final multivariate model was then constructed with significant (p \ 0.05) variables from the univariate analysis. Results. Of the 325 patients analyzed, 74 patients (22.8 %) failed initial RAI treatment, 53 (71.6 %) received additional RAI, 13 (17.6 %) received additional RAI followed by surgery, and the remaining 8 (10.8 %) were cured after thyroidectomy. The percentage of patients who failed decreased in a stepwise fashion as RAI dose increased. Similarly, the incidence of failure increased as the presenting T3 level increased. Sensitivity analysis revealed that RAI doses \12.5 mCi were associated with failure while initial T3 and free T4 levels of at least 4.5 pg/mL and 2.3 ng/dL, respectively, were associated with failure. In the final multivariate analysis, higher T4 (hazard ratio [HR] 1.13; 95 % confidence interval [CI] 1.02-1.26; p = 0.02) and methimazole treatment (HR 2.55; 95 % CI 1.22-5.33; p = 0.01) were associated with failure. Conclusions. Laboratory values at presentation can predict which patients with hyperthyroidism are at risk for failing RAI treatment. Higher doses of RAI or surgical referral may prevent the need for repeat RAI in selected patients.
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Hyperthyroidism impacts almost all organ systems, leading to agitation, insomnia, tachycardia, dyspnea, anemia, hyperdefecation, myopathy, and increased bone turnover. [1] [2] [3] The most common causes of hyperthyroidism are Graves' disease, toxic solitary nodule, or toxic multinodular goiter. 4 Three treatment options exist for patients suffering from hyperthyroidism. Radioactive iodine (RAI) and surgery are considered definitive treatment options since the purpose is to either destroy or remove all hyperfunctioning thyroid tissue. 4, 5 Antithyroid medications can be used for a defined period of time (12-18 months) in the hope of remission; however, these medications are generally not long-term treatment options due to their toxicities. Therefore, most patients suffering from hyperthyroidism must ultimately choose between RAI and surgery.
Radioactive iodine continues to be the treatment of choice for most US providers when given a hypothetical case of uncomplicated Graves' disease. 6, 7 Previously, guidelines favored RAI over surgery, but these most recent guidelines considered thyroidectomy as an equal treatment option to RAI. 8, 9 The reported recurrence rates after RAI treatment range from 10 to 40 % of patients, with more severe cases of hyperthyroidism associated with higher rates of failure. [10] [11] [12] Absolute contraindications to RAI are few and include pregnancy, lactation, and inability to comply with radiation safety guidelines after treatment. 8, 13 Beyond these few contraindications, providers lack specific selection criteria for treating hyperthyroid patients with RAI, medication, or surgery. 4 Although the use of surgery for the primary treatment of Graves' disease is increasing, surgical referral commonly occurs after other modalities have failed. Since RAI can lead to significant fibrosis and scarring of the thyroid, thyroidectomy after RAI becomes more challenging. Therefore, it would be advantageous for providers to be able to predict upfront which patients may be at high risk of RAI failure and instead undergo thyroidectomy as the initial treatment option. 14, 15 Amidst the uncertainty regarding the optimal therapy for hyperthyroidism, the purpose of this study is twofold. First, we describe a large, tertiary referral center's experience in treating hyperthyroidism with RAI and detail patterns of failure. Second, we identify factors associated with failure.
METHODS
After obtaining Institutional Review Board approval, we conducted a retrospective review of patients treated with RAI from 2007 to 2010 at our institution. We selected adult (C18 years of age) patients receiving RAI for hyperthyroidism. Children, pregnant women, and patients treated for thyroid cancer were excluded. Also excluded were patients lacking follow-up (\1 month) data in the medical record after their treatment date. For patients meeting these selection criteria, further details of their treatment for hyperthyroidism were abstracted from the electronic medical records, including medications, laboratory results, physical examination findings, demographics, co-morbidities, thyroid imaging, and doses of RAI. Patients were classified as having Graves' disease if they had either positive thyroid-stimulating hormone (TSH) receptorstimulating antibodies or homogenous uptake on radioiodine uptake scan.
Failure of RAI was defined as requiring treatment with an additional dose(s) of RAI and/or total thyroidectomy for the treatment of hyperthyroidism. Kaplan-Meier diseasefree survival estimates were plotted to analyze the timing of failures. Using a Cox proportional hazards model, we conducted multivariate analysis to identify factors associated with failure of RAI. All statistical analyses were performed using STATA version 12.1 (StataCorp, College Station, TX, USA).
RESULTS

Patient and Disease Characteristics
A total of 325 patients were included in this study. Nearly 73 % were female, and 84 % were Caucasian. The average age was 43.4 ± 15.5 years. This cohort was fairly healthy, with few co-morbidities (Table 1) .
Of the total cohort, 260 patients (80.3 %) were treated for Graves' disease, while 51 (15.7 %) had toxic multinodular goiter and 14 (4.3 %) had a solitary toxic nodule. Eightyseven patients (26.9 %) presented with eye disease (Table 1) .
As expected, this cohort presented with laboratory evidence of hyperthyroidism (Table 2 ). Accordingly, the average percentage uptake on radioiodine uptake was 47.5 ± 18.9 % ( Table 2 ). Detailed laboratory indices are given in Table 1 .
Initial Management of Hyperthyroidism and Failures
At presentation, nearly half of this cohort was treated with methimazole (48.2 %), 21.5 % were treated with propylthiouracil (PTU), 13.5 % received steroids, and 14.2 % were treated with b-blockers ( Table 2 ). Sixty patients (18.5 %) were treated with more than one antithyroid medication (methimazole, PTU, b-blockers, and/or steroids when administered specifically for hyperthyroidism).
The median dose of RAI administered to this cohort was 10.9 mCi, with a range of 5-37.7 mCi. Patients received RAI at a median of 8.2 months from presentation ( Table 2) .
A total of 74 patients (22.8 %) failed RAI, and the median time to retreatment was 10.4 months (interquartile range [IQR] 9.3). When considering the subset of patients who failed, we found that their median dose of RAI was significantly lower than those who did not fail (8.6 ± 4.5 mCi vs. 11.8 ± 7.2 mCi; p \ 0.01) ( Table 2) . Sixty percent of patients receiving B8 mCi failed. Fiftythree of the 74 patients (71.6 %) who failed RAI were treated with additional doses of RAI, 13 (17.6 %) received additional doses of RAI followed by surgery, and the remaining eight patients (10.8 %) were treated with surgery for their recurrence ( Table 2) .
The Kaplan-Meier estimates for RAI failure were plotted to further examine the time course for failures. The median follow-up time for the entire cohort was 1.2 years (IQR 1.6 years). When examining the Kaplan-Meier estimates, it appeared that there were both early and late failures ( Fig. 1) . We divided the entire follow-up time available into thirds, and 75.7 % of failures occurred in the first 1.3 years after RAI. Only 9.5 % of failures occurred in the middle period between 1.3 and 2.6 years, and nearly 15 % of failures occurred in the later third, after 2.6 years ( 
Univariate Analysis
To analyze the factors associated with failure of RAI, we conducted univariate analysis on all pre-treatment variables. Older age and female sex were associated with success of RAI Table 3 ). Graves' disease was associated with failure (HR 2.83; 95 % CI 1.22-6.54; p = 0.02), while toxic multinodular goiter was associated with treatment success (Table 3) . A higher heart rate at presentation and a greater uptake percentage on radioiodine uptake were associated with failure (Table 3) . More severe thyroid function laboratory tests at presentation were also associated with RAI failure (Table 3 ). Further analysis revealed that there was a stepwise increase in the proportion of failures with increasing T3 levels (electronic supplementary Fig. 1b) . A similar pattern was noted for T4 levels (data not shown). Of note, the proportion of patients failing decreased with increasing doses of RAI (electronic supplementary Fig. 1a ). An RAI dose less than 13 mCi was significantly associated with failure (HR 2.22; 95 % CI 1.29-3.84; p \ 0.01), while higher doses were protective against failure (Table 3) . Patients treated with methimazole or more than one antithyroid medication were also more likely to fail RAI (Table 3) .
Multivariate Analysis
Next we constructed a multivariate model using significant (p \ 0.05) variables from our univariate analysis. (Table 4) . Age, sex, disease etiology, presence of goiter, or co-morbidities were not significantly associated with RAI failure (Table 4) . Since our entire cohort included all types of hyperthyroidism, we repeated this analysis on just the subset of patients with Graves' disease (n = 260). Like the overall cohort, heart rate (HR 1.02; 95 % CI 1.00-1.04; p = 0.02), free T4[5 ng/dL (HR 2.23; 95 % CI 1.28-3.87; p \ 0.01), percentage uptake (HR 1.02; 95 % CI 1.00-1.04; p = 0.04), and methimazole use (HR 2.00; 95 % CI 1.08-3.70; p = 0.03) were independently associated with failure in the Graves' subset. Unlike the overall cohort, lower doses of RAI and lower TSH values at presentation did not independently predict failure in the multivariate model, although both were significant on univariate analysis.
Sensitivity Analysis
To provide clinically meaningful values, we conducted sensitivity analysis to identify thresholds for the continuous clinical variables significant in our multivariate model.
Initial free T4 and heart rate levels of at least 2.3 ng/dL and 78 beats per min were associated with failure. RAI doses \12.5 mCi were also associated with failure.
DISCUSSION
In this examination of a single tertiary referral center's experience with treatment of hyperthyroidism with RAI, nearly 23 % of patients failed RAI treatment. The vast majority of these failures (75.7 %) occurred within the first third of our follow-up time (1.3 years after treatment), but a significant portion (14.9 %) happened beyond 2.6 years after treatment. A higher heart rate at presentation or more severe laboratory indices of hyperthyroidism (lower TSH and higher free T4) were associated with failure. Importantly, lower doses of RAI (\13 mCi) were also associated with failure. These results can help clinicians in two ways: (1) identify patients at risk for failing RAI treatment and direct them to thyroidectomy; and (2) increase RAI doses for selected patients undergoing RAI.
In contrast to many studies on this topic, failure was defined here using a patient-centered designation-the need for repeat or alternate therapy for hyperthyroidism. Others have defined successful or failed treatment of hyperthyroidism based on thyroid function studies at defined timepoints. [16] [17] [18] Here, we did not make any divisions between persistence and recurrence, and instead opted for a more all-encompassing examination of failure of RAI. However, only 15 patients failed within 6 months of treatment. Historically, patients were treated with the goal of achieving euthyroidism, but the modern treatment strategy is to completely ablate the thyroid, rendering patients hypothyroid. 4 In one study, Kendall-Taylor and colleagues found that only 5.6 % of patients failed RAI at 1 year when the intent was complete ablation of the thyroid. 19 In this retrospective series, we could not ascertain the intention of the treating provider(s). A variety of different providers ([3), doses, and dosing strategies were used, but this enabled us to look at a range of doses and enabled us to analyze the impact of dosage on failure rates. Importantly, we examined thyroid size both in terms of the clinician's examination and largest dimension on ultrasound. Although goiter on examination was significant on univariate analysis (Table 3) , it did not independently predict failure in the multivariate model (Table 4) . Therefore, we feel a lower dose of RAI independently predicted failure regardless of thyroid size.
It is important to place the failure rate we found here in context with the failure rates for the other two treatment modalities-surgery and antithyroid medications. Antithyroid medications were associated with a much higher failure rate (52 %) compared with RAI (15 %) and surgery (10 %). 20 With a shift in surgical thinking away from subtotal and toward total thyroidectomy, this 10 % recurrence rate after surgery may reflect older literature. [21] [22] [23] Hence, although the failure rate after RAI is not negligible, it is certainly better than continued antithyroid medications. The failure rate for RAI reported here is slightly higher than the range of 14-20 % reported in the literature. 16, 18, 20, [24] [25] [26] This is likely a reflection of the variability in treatment strategies used by the physicians at our institution and the lack of a formal dosing algorithm. However, prospective studies report an even higher rate of failure than we did here in this retrospective series. For example, Metso and colleagues reported that 25 % of patients relapsed after a single dose of RAI. 27 In a randomized prospective study comparing RAI, surgery, and antithyroid medications for patients with Graves' disease, Torring et al. report a 21 % failure rate within the RAI group. When considering all patients who received more than one dose of RAI as a failure, then the rate of relapse in the trial by Torring et al. 10 exceeds 45 %. Although the selection criteria and definition of failure may differ somewhat between these studies and our results, it appears that a single dose of RAI fails in at least 20-25 % of all-comers, and patients should understand this when considering the various treatment options for hyperthyroidism. As mentioned above, the failure rate is much lower (5-6 %) when the intention is complete ablation of the thyroid, or hypothyroidism. Therefore, if patients choose RAI with the expectation that it will work the first time, then the results reported here support the concept that higher doses should be used for this purpose. 10, 19, 28 Alternatively, some patients might elect total thyroidectomy to eliminate the risk of recurrence altogether.
The relationship between dose and failure we found here is supported by the literature on this topic. Similar to these studies, we found that lower doses of RAI were associated with failure, while higher doses were protective. 16, 18, 24, 25 For example, Sztal-Mazer et al. 18 found that patients treated with B15 mCi experienced a 26 % failure rate. After the period of this study, our institution standardized its practice and now only administers doses greater than 8 mCi. It is hypothesized that higher doses carry additional risk for local side effects, such as radiation thyroiditis and salivary gland dysfunction, in addition to the development or exacerbation of opthalmopathy. 20, 29, 30 The cancer incidence is higher among those previously treated with RAI for Graves' disease, and there was a dose-response relationship. 31, 32 RAI also increased the risk of thyroid cancer in patients with toxic multinodular goiter, but the underlying etiology may be the disease itself. 31, 33 Unfortunately, we do not have accurate information regarding adverse outcomes from RAI in this study, but these risks must be balanced against the risk of recurrence.
Similar to our findings, others have also found that the percentage uptake 16 and higher pretreatment free T4 16, 24 were associated with failure. Finally, we also found that methimazole use predicted failure of RAI. Some evidence suggests that pre-treatment with antithyroid medications increases the risk of failure. 34 In one study, this occurred with PTU, but not methimazole. 35 We believe that methimazole is a marker for the severity of hyperthyroidism rather than intrinsically causing failure, but we continue to evaluate the use of preoperative medications in patients undergoing surgery.
Although this study is one of the largest to date examining failure of RAI, it is limited by its retrospective nature. These results may reflect the use and referral patterns unique to our center. In addition, we did not capture data related to the dosing strategy or rationale. These data reflect the practice of several different ([3) nuclear medicine specialists. While many calculate an RAI dose based on estimated thyroid weights, these are simply estimations subject to considerable error and bias. Instead, we have included measured thyroid size by ultrasound in our univariate analysis, and these measures did not meet statistical criteria for inclusion in our final model. Furthermore, we have repeated our analysis by normalizing the doses to the percentage uptake (mCi/% uptake) and achieved very similar results (data not shown). Although our median follow-up time exceeds 1 year, we may not have captured failures treated outside our center. Those with little followup data (\1 month) were excluded. Finally, while this cohort is purposefully heterogeneous to reflect all etiologies of hyperthyroidism, this was controlled for in our multivariate analysis.
CONCLUSIONS
In this large retrospective analysis of RAI treatment for hyperthyroidism with over 4 years of follow-up, nearly 23 % of patients failed RAI, requiring a second dose or surgery in order to achieve cure. More severe laboratory indices (TSH, free T4) and a higher heart rate at presentation independently predict failure of RAI in the treatment of hyperthyroidism. Patients who present with these findings may prefer thyroidectomy as their initial definitive treatment option for hyperthyroidism in order to avoid relapse. Nonetheless, the decision regarding the optimal initial therapy remains complex and must consider many different factors, including co-morbidities, living situation, smoking status, and the presence or absence of eye disease. Importantly, higher doses of RAI also protect against failure. This information can assist providers in counseling patients about their treatment options, selecting patients for surgery, or adjusting RAI doses to minimize the risk of failure.
